417 related articles for article (PubMed ID: 3612533)
1. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
4. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; GarcĂa-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
6. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
7. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
Komuro Y; Imanishi N; Uchida M; Morooka S
Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.
Yamada T; Tomioka K; Saito M; Horie M; Mase T; Hara H; Nagaoka H
Arch Int Pharmacodyn Ther; 1990; 308():123-36. PubMed ID: 2099131
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of platelet activating factor receptor binding and stimulated phosphoinositide-specific phospholipase C in rabbit platelets.
Morrison WJ; Shukla SD
J Pharmacol Exp Ther; 1989 Sep; 250(3):831-5. PubMed ID: 2550620
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
13. CV-3988 - a specific antagonist of platelet activating factor (PAF).
Terashita Z; Tsushima S; Yoshioka Y; Nomura H; Inada Y; Nishikawa K
Life Sci; 1983 Apr; 32(17):1975-82. PubMed ID: 6403793
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
[TBL] [Abstract][Full Text] [Related]
16. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412.
Handley DA; Van Valen RG; Melden MK; Houlihan WJ; Saunders RN
J Pharmacol Exp Ther; 1988 Nov; 247(2):617-23. PubMed ID: 3183958
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
Hwang SB; Li CL; Lam MH; Shen TY
Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
[TBL] [Abstract][Full Text] [Related]
18. Histamine release from rabbit platelets by platelet-activating factor (PAF).
Nakahodo K; Saitoh S; Nakamura M; Kosugi T
Arerugi; 1994 Mar; 43(3):501-10. PubMed ID: 7515227
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by glaucocalyxin A of aggregation of rabbit platelets induced by ADP, arachidonic acid and platelet-activating factor, and inhibition of [3H]-PAF binding.
Bin Z; Kun L
Thromb Haemost; 1992 Apr; 67(4):458-60. PubMed ID: 1631795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]